- Home
- ABUS vs PAHC Comparison
ABUS vs PAHC Comparison
Compare ABUS & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- PAHC
- Stock Information
- Founded
- ABUS N/A
- PAHC 1946
- Country
- ABUS United States
- PAHC United States
- Employees
- ABUS N/A
- PAHC N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- PAHC Biotechnology: Pharmaceutical Preparations
- Sector
- ABUS Health Care
- PAHC Health Care
- Exchange
- ABUS Nasdaq
- PAHC Nasdaq
- Market Cap
- ABUS 697.3M
- PAHC 682.5M
- IPO Year
- ABUS N/A
- PAHC 2014
- Fundamental
- Price
- ABUS $3.21
- PAHC $21.69
- Analyst Decision
- ABUS Strong Buy
- PAHC Sell
- Analyst Count
- ABUS 4
- PAHC 4
- Target Price
- ABUS $5.50
- PAHC $20.50
- AVG Volume (30 Days)
- ABUS 903.4K
- PAHC 186.7K
- Earning Date
- ABUS 11-06-2024
- PAHC 02-05-2025
- Dividend Yield
- ABUS N/A
- PAHC 2.21%
- EPS Growth
- ABUS N/A
- PAHC N/A
- EPS
- ABUS N/A
- PAHC 0.43
- Revenue
- ABUS $6,742,000.00
- PAHC $1,046,762,000.00
- Revenue This Year
- ABUS N/A
- PAHC $27.25
- Revenue Next Year
- ABUS N/A
- PAHC $14.13
- P/E Ratio
- ABUS N/A
- PAHC $50.47
- Revenue Growth
- ABUS N/A
- PAHC 7.17
- 52 Week Low
- ABUS $2.21
- PAHC $10.04
- 52 Week High
- ABUS $4.72
- PAHC $25.98
- Technical
- Relative Strength Index (RSI)
- ABUS 33.77
- PAHC 37.79
- Support Level
- ABUS $3.13
- PAHC $21.12
- Resistance Level
- ABUS $3.61
- PAHC $24.42
- Average True Range (ATR)
- ABUS 0.17
- PAHC 0.85
- MACD
- ABUS -0.03
- PAHC -0.22
- Stochastic Oscillator
- ABUS 12.12
- PAHC 17.27
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About PAHC Phibro Animal Health Corporation
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.